These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 23480437)

  • 1. Streamlining hit discovery and optimization with a yoctoliter scale DNA reactor.
    Heitner TR; Hansen NJ
    Expert Opin Drug Discov; 2009 Nov; 4(11):1201-13. PubMed ID: 23480437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A yoctoliter-scale DNA reactor for small-molecule evolution.
    Hansen MH; Blakskjaer P; Petersen LK; Hansen TH; Højfeldt JW; Gothelf KV; Hansen NJ
    J Am Chem Soc; 2009 Jan; 131(3):1322-7. PubMed ID: 19123795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Affinity-based screening techniques for enhancing lead discovery.
    Comess KM; Schurdak ME
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):411-6. PubMed ID: 15338950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 20 years of DNA-encoded chemical libraries.
    Mannocci L; Leimbacher M; Wichert M; Scheuermann J; Neri D
    Chem Commun (Camb); 2011 Dec; 47(48):12747-53. PubMed ID: 22083211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads.
    Bergsdorf C; Ottl J
    Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fidelity by design: Yoctoreactor and binder trap enrichment for small-molecule DNA-encoded libraries and drug discovery.
    Blakskjaer P; Heitner T; Hansen NJ
    Curr Opin Chem Biol; 2015 Jun; 26():62-71. PubMed ID: 25732963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which aspects of HTS are empirically correlated with downstream success?
    Bender A; Bojanic D; Davies JW; Crisman TJ; Mikhailov D; Scheiber J; Jenkins JL; Deng Z; Hill WA; Popov M; Jacoby E; Glick M
    Curr Opin Drug Discov Devel; 2008 May; 11(3):327-37. PubMed ID: 18428086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lead generation and examples opinion regarding how to follow up hits.
    Orita M; Ohno K; Warizaya M; Amano Y; Niimi T
    Methods Enzymol; 2011; 493():383-419. PubMed ID: 21371599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early phase drug discovery: cheminformatics and computational techniques in identifying lead series.
    Duffy BC; Zhu L; Decornez H; Kitchen DB
    Bioorg Med Chem; 2012 Sep; 20(18):5324-42. PubMed ID: 22938785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent trends and observations in the design of high-quality screening collections.
    Renner S; Popov M; Schuffenhauer A; Roth HJ; Breitenstein W; Marzinzik A; Lewis I; Krastel P; Nigsch F; Jenkins J; Jacoby E
    Future Med Chem; 2011 Apr; 3(6):751-66. PubMed ID: 21554080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of diversity-based, high-throughput screening on drug discovery: "chance favours the prepared mind".
    Snowden M; Green DV
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):553-8. PubMed ID: 18600571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process.
    Danielson UH
    Future Med Chem; 2009 Nov; 1(8):1399-414. PubMed ID: 21426056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hit and lead generation: beyond high-throughput screening.
    Bleicher KH; Böhm HJ; Müller K; Alanine AI
    Nat Rev Drug Discov; 2003 May; 2(5):369-78. PubMed ID: 12750740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomics and systems biology--how relevant are the developments to veterinary pharmacology, toxicology and therapeutics?
    Witkamp RF
    J Vet Pharmacol Ther; 2005 Jun; 28(3):235-45. PubMed ID: 15953196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hit discovery and hit-to-lead approaches.
    Keseru GM; Makara GM
    Drug Discov Today; 2006 Aug; 11(15-16):741-8. PubMed ID: 16846802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug discovery with DNA-encoded chemical libraries.
    Buller F; Mannocci L; Scheuermann J; Neri D
    Bioconjug Chem; 2010 Sep; 21(9):1571-80. PubMed ID: 20681509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Median absolute deviation to improve hit selection for genome-scale RNAi screens.
    Chung N; Zhang XD; Kreamer A; Locco L; Kuan PF; Bartz S; Linsley PS; Ferrer M; Strulovici B
    J Biomol Screen; 2008 Feb; 13(2):149-58. PubMed ID: 18216396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Streamlining lead discovery by aligning in silico and high-throughput screening.
    Davies JW; Glick M; Jenkins JL
    Curr Opin Chem Biol; 2006 Aug; 10(4):343-51. PubMed ID: 16822701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.